Immunovant remains a high-risk, high-reward play, hinging on the success of its next-gen candidate IMVT-1402. Click to read my latest analysis of IMVT stock.

Premiums for people who get their insurance through Healthcare.gov are rising about 30% on average. Without the enhanced ...

A new lawsuit takes on computer-assisted wagering. Can the industry survive if the suit fails? Can it survive if the suit ...

An estimated 18.4 million workers with a college degree in the U.S. will retire from now through 2032, according to Georgetown University’s Center on Education and the Workforce. This is far greater ...

An analysis of admissions data for 22 selective colleges suggests a decrease in the percentage of black freshmen admitted in ...

After decades of gradual growth, the number of Black students enrolling at many elite colleges has dropped in the two years ...

Karthik Raja, chief analytics and AI officer at the sprawling 16-state health system, says artificial intelligence is "not ...

Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...

Background Most mental health disorders are first experienced during childhood. There are evidence-based treatments, but it ...

Background The development of non-sputum-based tests is an urgent priority to increase access to tuberculosis (TB) diagnostic ...

This study offers a valuable methodological advance by introducing a gene panel selection approach that captures combinatorial specificity to define cell identity. The findings address key limitations ...